25.37
免疫疗法是一种增强或操纵免疫系统来对抗疾病(包括癌症)的治疗方法。例如,通过接种针对导致癌症的病毒(如乙肝病毒和人乳头瘤病毒)的疫苗来刺激免疫反应,可以预防这些疾病。尽管如此,一些癌细胞由于其快速突变和分裂,它们能够逃避免疫系统的攻击。免疫系统对许多癌症的反应涉及三个阶段:消除、平衡和逃逸。
人们已…
癌症免疫疗法通过使用疫苗、溶瘤病毒、活化的患者T细胞以及免疫检查点调节剂,帮助机体免疫系统识别并清除癌细胞。
治疗性疫苗采用患者自身的细胞(如树突状细胞)制备,这些细胞被加载肿瘤抗原,以刺激免疫反应。
或者,溶瘤病毒疗法利用天然或经过基因改造的病毒选择性地感染癌细胞。
例如,T-VEC 是一种经过基因改造的单纯疱疹病毒,可选择性地裂解癌细胞并释放肿瘤抗原,以引发更强的细胞毒性T细胞反应。
相比之下,过继性细胞疗法会修饰患者的T细胞,这些T细胞可被编辑以表达嵌合抗原受体(CARs)。
一旦回输,这些CAR T细胞即可直接结合并杀伤特定的癌细胞。
一些肿瘤细胞利用免疫检查点蛋白(如T细胞上的CTLA-4)的结合伴侣,下调免疫应答。
抗体(如伊匹单抗)是一类免疫检查点抑制剂,可阻断CTLA-4与肿瘤细胞的相互作用,从而增强T细胞对肿瘤抗原的增殖反应。
View the full transcript and gain access to JoVE Core videos
Q1: How do cancer treatment vaccines work to fight tumors?
Cancer treatment vaccines are designed using dendritic cells loaded with tumor antigens from the patient's own cancer cells. These antigen-presenting cells stimulate an immune response, training the body to recognize and attack cancer cells. This approach leverages the patient's adaptive immune system to target malignant cells specifically.
Q2: What is CAR T cell therapy and how does it eliminate cancer?
Adoptive cell therapy modifies a patient's T cells to express chimeric antigen receptors, or CARs, which enable direct recognition of cancer cells. Once reinfused into the patient, CAR T cells bind to specific tumor antigens and destroy cancer cells. This personalized approach harnesses the patient's own immune cells as targeted cancer fighters.
Q3: How do oncolytic viruses like T-VEC treat cancer?
Oncolytic virus therapy uses genetically modified viruses, such as T-VEC, a herpes virus variant, to selectively infect and lyse cancer cells. When tumor cells rupture, they release tumor antigens that trigger additional cytotoxic T cell responses. This dual mechanism combines direct cell destruction with immune system activation.
Q4: What role do immune checkpoint inhibitors play in cancer treatment?
Tumor cells exploit immune checkpoint proteins like CTLA-4 on T cells to suppress immune responses. Checkpoint inhibitor antibodies, such as ipilimumab, block these interactions, preventing tumor cells from evading immunity. By removing this inhibition, these antibodies enhance T cell proliferation and activation against tumor antigens.
Q5: Why do some cancer cells escape the immune system?
Cancer cells evade immunity through rapid mutation and division, allowing them to avoid recognition by immune surveillance mechanisms. The immune response to cancer involves three phases: elimination, equilibrium, and escape. Understanding these phases helps researchers develop strategies to enhance early immune responses and prevent tumor escape.
Q6: How is immunotherapy administered to cancer patients?
Immunotherapy can be delivered through multiple routes including intravenous, oral, topical, and intravesical administration. Treatment frequency and duration depend on cancer type, stage, the specific immunotherapy used, and the patient's response. Regular medical check-ups and tests monitor treatment effectiveness and guide adjustments.
Q7: What are the main types of cancer immunotherapy approaches?
Cancer immunotherapy includes several strategies: immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines, and immune system modulators. Each approach targets different mechanisms to enhance the body's ability to recognize and eliminate cancer cells. These therapies work by boosting or manipulating immune responses against malignant tumors.